Pneumagen logo.jpg
Pneumagen Highlights Broad-Spectrum Antiviral Activity of First-in-Class Intranasal Drug Neumifil in New Publication
July 03, 2024 04:00 ET | Pneumagen Ltd
Pneumagen has previously reported positive results from both Phase 1 and a clinical proof of concept Phase 2 Human Influenza Challenge study demonstrating the potential of NeumifilNew preclinical...
Traws Pharma blue.png
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
May 16, 2024 09:29 ET | Traws Pharma, Inc.
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
Logo.png
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
May 13, 2024 08:00 ET | Cocrystal Pharma, Inc.
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the second quarter of 2024 Enrollment completed in...
Pneumagen logo.jpg
Pneumagen to Present Phase 2 Clinical Data on Neumifil, its Broad-Spectrum Antiviral, Intranasal Drug for Viral Respiratory Tract Infections, at ATS 2024
May 02, 2024 07:00 ET | Pneumagen Ltd
Data to be presented in oral and ePoster presentations St Andrews, UK – 2 May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for...
Dyadic Logo Current.jpg
Dyadic Announces Change in Board and Management Leadership Roles
March 28, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...
Dyadic Logo Current.jpg
CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
March 11, 2024 09:57 ET | Dyadic International, Inc.
In a release issued under the same headline on Monday, March 11th by Dyadic International, Inc. (NASDAQ: DYAI), please note that the city in the dateline should be JUPITER, Fla. not JUNIPER, Fla. The...
Dyadic Logo Current.jpg
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
March 11, 2024 08:30 ET | Dyadic International, Inc.
JUNIPER, Fla., March 11, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Logo Current.jpg
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
February 21, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced...
Dyadic Logo Current.jpg
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
February 06, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a...
Dyadic Logo Current.jpg
Dyadic Attends Investor Events in December
November 30, 2023 08:30 ET | Dyadic International, Inc.
Dyadic Attends Investor Events in December